Reviewing the Potential of Psychedelics for the Treatment of PTSD
Open accessThe DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Abstract
There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not just novel compounds but novel approaches for the treatment of PTSD. A promising new approach involves the use of psychedelic drugs. Within the past few years, 2 psychedelics have received breakthrough designations for psychiatric indications from the US Food and Drug Administration, and several psychedelics are currently being investigated for the treatment of PTSD. This review discusses 4 types of compounds: 3,4-methylenedioxymethamphetamine, ketamine, classical psychedelics (e.g., psilocybin and lysergic acid diethylamide), and cannabinoids. We describe the therapeutic rationale, the setting in which they are being administered, and their current state of evidence in the treatment of PTSD. Each compound provides unique qualities for the treatment of PTSD, from their use to rapidly target symptoms to their use as adjuncts to facilitate psychotherapeutic treatments. Several questions are formulated that outline an agenda for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have also pointed out a potential of use of MDMA assisted psychotherapy as a minimal risk therapeutic method that works by reducing fear response to traumatic memories, while enhancing introspection and increasing interpersonal trust, which improves the patient-therapist relationship and so, the effectiveness of the therapy (Krediet et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Krediet et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To our knowledge, MDMA treatment efficacy is so far mainly assessed in PTSD patients, indicating moderate to large effects (Krediet et al., 2020;Bahji et al., 2020).”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Krediet et al., 2020
The cited source says what the claim attributes to it.
In the citing paper
“Ketamine has also been studied because of the rapid antidepressant properties that it exhibits (Krediet et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Krediet et al., 2020
The cited source says what the claim attributes to it.
In the citing paper
“Ketamine has also been considered for the treatment of PTSD, although information on this matter is still lacking (Krediet et al., 2020; Reiff et al., 2020).”
From Virtual reality and psychedelics for the treatment of psychiatric disease: A systematic literature review (2020) · doi:10.36131/cnfioritieditore20200606 · cites this paper as Krediet et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05249-5 · Cited by 359 · cited 3×
“Integrated within a psychotherapeutic treatment, 2 to 3 sessions with MDMA have shown the ability to induce significant and sustained reductions in PTSD symptoms (Mithoefer et al., 2019).”
BackgroundMethodRetractedAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169 · cited 1×
“pain relief, multiple sclerosis and epilepsy) have been growing again (Whiting et al., 2015; Haney and Hill, 2018).”
BackgroundSynaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 2×
“Psilocybin has been studied for the treatment of depression (Carhart-Harris et al., 2016, 2017), tobacco and alcohol addiction (Johnson et al., 2014, 2017; Bogenschutz et al., 2015, 2018), obsessive-compulsive disorder (Moreno et al., 2006), and depression and anxiety in patients with…”
BackgroundNichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 2×
“As with the use of ketamine for depression (Murrough et al., 2013), research suggests that the therapeutic effects of ketamine on PTSD can be enhanced – both in strength and duration – with repeated infusions.”
BackgroundPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Li, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Psychotherapy for Military-Related PTSD: A Review of Randomized Clinical Trials
Steenkamp, M. M., Litz, B. T., Hoge, C. W., & Marmar, C. R. (2015) · JAMA · doi:10.1001/jama.2015.8370 · Cited by 958
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H., Rodriguez, V., Jongsma, H. E., Ferraro, L., La Cascia, C., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30048-3 · Cited by 875
Post-traumatic stress disorder.
Yehuda, R., Hoge, C. W., McFarlane, A. C., Vermetten, E., Lanius, R. A., Nievergelt, C. M., Hobfoll, S. E., Koenen, K. C., Neylan, T. C., & Hyman, S. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.57 · Cited by 870
Self-citationRoseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789 · cited 1×
“, 2015, 2018), obsessive-compulsive disorder (Moreno et al., 2006), and depression and anxiety in patients with life-threatening diagnoses (Grob et al.”
BackgroundMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
History of cannabis as a medicine: a review
Zuardi, A. W. (2006) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462006000200015 · Cited by 730
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 1×
“Psychedelic drugs (sometimes referred to as hallucinogens or entactogens) refer to a category of compounds that can induce a wide range of psychological, cognitive, emotional, and physical effects (Nichols, 2004; Vollenweider and Kometer, 2010).”
BackgroundLong-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674
Practical considerations in medical cannabis administration and dosing
MacCallum, C. A., & Russo, E. B. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.004 · Cited by 663
Neurobiological Interactions Between Stress and the Endocannabinoid System
Morena, M., Patel, S., Bains, J. S., & Hill, M. N. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.166 · Cited by 660
Sota, J., Insalaco, A., Cimaz, R., Alessio, M., Cattalini, M., Gallizzi, R., Maggio, M. C., Lopalco, G., La Torre, F., Fabiani, C., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01526 · Cited by 616
Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L.-B., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.62 · Cited by 613
Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817709585 · Cited by 589 · cited 1×
“emotionally vulnerable during the days following the experience, which stresses the importance of psychological support afterwards (Watts et al., 2017).”
BackgroundHasin, D. S., Kerridge, B. T., Saha, T. D., Huang, B., Pickering, R., Smith, S. M., Jung, J., Zhang, H., & Grant, B. F. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15070907 · Cited by 579
Black, N., Stockings, E., Campbell, G., Tran, L. T., Zagic, D., Hall, W. D., Farrell, M., & Degenhardt, L. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30401-8 · Cited by 564
Treating PTSD: A Review of Evidence-Based Psychotherapy Interventions
Watkins, L. E., Sprang, K. R., & Rothbaum, B. O. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00258 · Cited by 563 · cited 1×
“However, 40–60% of patients do not respond adequately (Haagen et al., 2015; Steenkamp et al., 2017; Watkins et al., 2018).”
BackgroundPsilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
The pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465 · cited 1×
“The psychological effects of psilocybin last from 3 to 6 hours (Passie et al., 2002) and those of LSD last from 8 to 10 hours (Passie et al.”
BackgroundSelf-citationThe pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455
Self-citationMithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30135-4 · Cited by 439 · cited 3×
“These results were replicated in two other studies (Mithoefer et al., 2018; Ot’alora et al., 2018), in which MDMAtreated subjects also showed increases in post-traumatic growth.”
BackgroundResultPharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis
Hoskins, M., Pearce, J., Bethell, A., Dankova, L., Barbui, C., Tol, W. A., van Ommeren, M., de Jong, J., Seedat, S., Chen, H., et al. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.148551 · Cited by 418
Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
Roseman, L., Haijen, E., Idialu-Ikato, K., Kaelen, M., Watts, R., & Carhart-Harris, R. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855974 · Cited by 413
Norrholm, S. D., Jovanovic, T., Olin, I. W., Sands, L. A., Karapanou, I., Bradley, B., & Ressler, K. J. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.013 · Cited by 397
Scott, J. C., Slomiak, S. T., Jones, J. D., Rosen, A. F. G., Moore, T. M., & Gur, R. C. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0335 · Cited by 391 · cited 1×
“There is an ongoing discussion about the persistence of such effects (Schreiner and Dunn, 2012; Scott et al., 2018).”
BackgroundMithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar-Klosinski, B., Michel, Y., Brewerton, T. D., & Doblin, R. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112456611 · Cited by 376
McGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2015) · Psychological Medicine · doi:10.1017/s0033291714001603 · Cited by 373
Psychedelics as Medicines: An Emerging New Paradigm
Nichols, D., Johnson, M., & Nichols, C. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.557 · Cited by 370
Gender differences in the subjective effects of MDMA
Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001) · Psychopharmacology · doi:10.1007/s002130000648 · Cited by 360 · cited 1×
“In some cases, a slightly depressed mood has been reported (Liechti et al., 2001).”
BackgroundMDMA enhances emotional empathy and prosocial behavior
Hysek, C. M., Schmid, Y., Simmler, L. D., Domes, G., Heinrichs, M., Eisenegger, C., Preller, K. H., Quednow, B. B., & Liechti, M. E. (2014) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nst161 · Cited by 356
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354 · cited 4×
“flashbacks) when used in medically supervised settings (Cohen, 1960; Johnson et al., 2018; Malleson, 1971).”
BackgroundMethodInfluentialKetamine administration in depressive disorders: a systematic review and meta-analysis
Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., Micoulaud-Franchi, J.-A., Richieri, R., Courtet, P., Abbar, M., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3664-5 · Cited by 339
Oxytocin-dependent reopening of a social reward learning critical period with MDMA
Nardou, R., Lewis, E. M., Rothhaas, R., Xu, R., Yang, A., Boyden, E., & Dölen, G. (2019) · Nature · doi:10.1038/s41586-019-1075-9 · Cited by 334 · cited 1×
“, 2007), and a recent study found that a single dose of MDMA in mice reopens the critical period for social reward learning, which required activation of oxytocin receptors in the nucleus accumbens, and endures beyond the acute effects of the drug (Nardou et al., 2019).”
BackgroundKraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.010 · Cited by 323
Jetly, R., Heber, A., Fraser, G., & Boisvert, D. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.11.002 · Cited by 321
McKenna, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.03.002 · Cited by 321
LSD‐induced entropic brain activity predicts subsequent personality change
Lebedev, A. V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D. J., & Carhart‐Harris, R. L. (2016) · Human Brain Mapping · doi:10.1002/hbm.23234 · Cited by 303
A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis
Berman, P., Futoran, K., Lewitus, G. M., Mukha, D., Benami, M., Shlomi, T., & Meiri, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-32651-4 · Cited by 292
Schreiner, A. M., & Dunn, M. E. (2012) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0029117 · Cited by 289
LYSERGIC ACID DIETHYLAMIDE: SIDE EFFECTS AND COMPLICATIONS
COHEN, S. (1960) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196001000-00005 · Cited by 287
Francati, V., Vermetten, E., & Bremner, J. D. (2007) · Depression and Anxiety · doi:10.1002/da.20208 · Cited by 286
Self-citationFraser, G. A. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00071.x · Cited by 283 · cited 2×
“These results confirm tentative findings from an open label chart review study of nabilone in 47 PTSD patients (Fraser, 2009) and a retrospective study on 104 male inmates (Cameron et al.”
ResultDanforth, A. L., Grob, C. S., Struble, C., Feduccia, A. A., Walker, N., Jerome, L., Yazar-Klosinski, B., & Emerson, A. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5010-9 · Cited by 280 · cited 1×
“, 2019), and social anxiety in autistic adults (Danforth et al., 2018).”
BackgroundThe hidden therapist: evidence for a central role of music in psychedelic therapy
Kaelen, M., Giribaldi, B., Raine, J., Evans, L., Timmerman, C., Rodriguez, N., Roseman, L., Feilding, A., Nutt, D., & Carhart-Harris, R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4820-5 · Cited by 267
Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3579-0 · Cited by 266 · cited 1×
“Both psilocybin (Catlow et al., 2013) and DMT (Cameron et al.”
BackgroundThe harmful health effects of recreational ecstasy: a systematic review of observational evidence
Rogers, G., Elston, J., Garside, R., Roome, C., Taylor, R., Younger, P., Zawada, A., & Somerville, M. (2009) · Health Technology Assessment · doi:10.3310/hta13060 · Cited by 266
Krystal, J. H., Davis, L. L., Neylan, T. C., A. Raskind, M., Schnurr, P. P., Stein, M. B., Vessicchio, J., Shiner, B., Gleason, T. D., & Huang, G. D. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.007 · Cited by 265 · cited 4×
“Adding MDMA sessions to this approach could be particularly useful, as MDMA has shown to increase empathy (Kuypers et al., 2017) and interpersonal trust (Schmid et al., 2014).”
BackgroundMethodInfluentialCannabinoid Modulation of Amygdala Reactivity to Social Signals of Threat in Humans
Phan, K. L., Angstadt, M., Golden, J., Onyewuenyi, I., Popovska, A., & de Wit, H. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5603-07.2008 · Cited by 251
Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0569-3 · Cited by 247
The efficacy of recommended treatments for veterans with PTSD: A metaregression analysis
Haagen, J. F. G., Smid, G. E., Knipscheer, J. W., & Kleber, R. J. (2015) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.06.008 · Cited by 246
Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research
Krupitsky, E. M., & Grinenko, A. Y. (1997) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1997.10400185 · Cited by 246
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA
Mithoefer, M. C., Grob, C. S., & Brewerton, T. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00576-3 · Cited by 239
Evidence for the Risks and Consequences of Adolescent Cannabis Exposure
Levine, A., Clemenza, K., Rynn, M., & Lieberman, J. (2017) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.12.014 · Cited by 239
Hill, M. N., Campolongo, P., Yehuda, R., & Patel, S. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.162 · Cited by 239
Thompson, M. R., Callaghan, P. D., Hunt, G. E., Cornish, J. L., & McGregor, I. S. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.02.032 · Cited by 237 · cited 1×
“Oxytocin levels have been shown to mediate the prosocial effects of MDMA in animal studies (Thompson et al., 2007), and a recent study found that a single dose of MDMA in mice reopens the critical period for social reward learning, which required activation of oxytocin receptors in the nucleus…”
BackgroundSutcliffe, P., Hummel, S., Simpson, E., Young, T., Rees, A., Wilkinson, A., Hamdy, F., Clarke, N., & Staffurth, J. (2009) · Health Technology Assessment · doi:10.3310/hta13050 · Cited by 237
Ot’alora G, M., Grigsby, J., Poulter, B., Van Derveer, J. W., Giron, S. G., Jerome, L., Feduccia, A. A., Hamilton, S., Yazar-Klosinski, B., Emerson, A., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118806297 · Cited by 226
Reconsolidation and the dynamic nature of memory
Nader, K. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021782 · Cited by 221 · cited 2×
“The glutamate system has shown to play an essential role in several memory processes, such as reconsolidation and extinction learning (Nader, 2015).”
BackgroundDore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1587556 · Cited by 217
Feduccia, A. A., & Mithoefer, M. C. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.003 · Cited by 217
Reconsolidation and the Dynamic Nature of Memory
Nader, K. (2016) · Novel Mechanisms of Memory · doi:10.1007/978-3-319-24364-1_1 · Cited by 216
Goetter, E. M., Bui, E., Ojserkis, R. A., Zakarian, R. J., Brendel, R. W., & Simon, N. M. (2015) · Journal of Traumatic Stress · doi:10.1002/jts.22038 · Cited by 215
Medicinal use of cannabis based products and cannabinoids
Freeman, T. P., Hindocha, C., Green, S. F., & Bloomfield, M. A. P. (2019) · BMJ · doi:10.1136/bmj.l1141 · Cited by 213
Soler, J., Elices, M., Franquesa, A., Barker, S., Friedlander, P., Feilding, A., Pascual, J. C., & Riba, J. (2016) · Psychopharmacology · doi:10.1007/s00213-015-4162-0 · Cited by 209
Bouso, J. C., Doblin, R., Farré, M., Alcázar, M. Á., & Gómez-Jarabo, G. (2008) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2008.10400637 · Cited by 205
LSD enhances the emotional response to music
Kaelen, M., Barrett, F. S., Roseman, L., Lorenz, R., Family, N., Bolstridge, M., Curran, H. V., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4014-y · Cited by 201
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
Kuypers, K. P. C., Riba, J., de la Fuente Revenga, M., Barker, S., Theunissen, E. L., & Ramaekers, J. G. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4377-8 · Cited by 201
Sampedro, F., de la Fuente Revenga, M., Valle, M., Roberto, N., Domínguez-Clavé, E., Elices, M., Luna, L. E., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx036 · Cited by 200
The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents*
Freudenmann, R. W., Öxler, F., & Bernschneider‐Reif, S. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01511.x · Cited by 199
Roitman, P., Mechoulam, R., Cooper-Kazaz, R., & Shalev, A. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0212-3 · Cited by 197
Effect of Psilocybin on Empathy and Moral Decision-Making
Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I., & Vollenweider, F. X. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx047 · Cited by 197 · cited 1×
“Other acute effects that substantiate their potential therapeutic role in the treatment of PTSD, include increases in emotional empathy (Pokorny et al., 2017), increases in creative divergent thinking (Kuypers et al.”
BackgroundSingle Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin Dependence
Krupitsky, E. M., Burakov, A. M., Dunaevsky, I. V., Romanova, T. N., Slavina, T. Y., & Grinenko, A. Y. (2007) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2007.10399860 · Cited by 183
Carhart-Harris, R. L., Murphy, K., Leech, R., Erritzoe, D., Wall, M. B., Ferguson, B., Williams, L. T. J., Roseman, L., Brugger, S., De Meer, I., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.015 · Cited by 178
Moreira, F. A., & Wotjak, C. T. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_16 · Cited by 177 · cited 1×
“Especially if used in higher doses, cannabinoids can induce anxiety (Moreira and Wotjak, 2009).”
BackgroundKometer, M., Pokorny, T., Seifritz, E., & Volleinweider, F. X. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4026-7 · Cited by 176
Feduccia, A. A., Jerome, L., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00650 · Cited by 172
Cameron, C., Watson, D., & Robinson, J. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000180 · Cited by 171
Effects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
Cameron, L. P., Benson, C. J., Dunlap, L. E., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00134 · Cited by 171
Cannabinoid facilitation of fear extinction memory recall in humans
Rabinak, C. A., Angstadt, M., Sripada, C. S., Abelson, J. L., Liberzon, I., Milad, M. R., & Phan, K. L. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.063 · Cited by 163
Gamma, A. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00130-5 · Cited by 162
Wagner, M. T., Mithoefer, M. C., Mithoefer, A. T., MacAulay, R. K., Jerome, L., Yazar-Klosinski, B., & Doblin, R. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117711712 · Cited by 160 · cited 1×
“7 treatment with MDMA-assisted psychotherapy and reductions in PTSD symptoms (Wagner et al. 2017).”
MethodAlbott, C. S., Lim, K. O., Forbes, M. K., Erbes, C., Tye, S. J., Grabowski, J. G., Thuras, P., Batres-y-Carr, T. M., Wels, J., & Shiroma, P. R. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m11634 · Cited by 159
Cognitive-behavioral conjoint therapy for PTSD: Harnessing the healing power of relationships.
Monson, C. M., & Fredman, S. J. (2012) · Cited by 159
Mott, J. M., Mondragon, S., Hundt, N. E., Beason‐Smith, M., Grady, R. H., & Teng, E. J. (2014) · Journal of Traumatic Stress · doi:10.1002/jts.21927 · Cited by 157
Differential effects of MDMA and methylphenidate on social cognition
Schmid, Y., Hysek, C. M., Simmler, L. D., Crockett, M. J., Quednow, B. B., & Liechti, M. E. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114542454 · Cited by 155 · cited 1×
“, 2013), pleasantness of affective touch (De Wit and Bershad, 2019), and subjective ratings of closeness to others, openness, and trust (Schmid et al., 2014).”
BackgroundPsychedelic Drugs in Biomedicine
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R., Nichols, D. E., & Kalueff, A. V. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.08.003 · Cited by 155 · cited 2×
“Although many questions remain about the mechanisms of action and efficacy, psychedelic drugs have seen a renaissance in research on their therapeutic potential, ranging from the treatment of depression to substance use disorders and PTSD (Kyzar et al., 2017; Curran et al., 2018).”
BackgroundBonn‐Miller, M. O., Vujanovic, A. A., Feldner, M. T., Bernstein, A., & Zvolensky, M. J. (2007) · Journal of Traumatic Stress · doi:10.1002/jts.20243 · Cited by 149
Cipriani, A., Williams, T., Nikolakopoulou, A., Salanti, G., Chaimani, A., Ipser, J., Cowen, P. J., Geddes, J. R., & Stein, D. J. (2018) · Psychological Medicine · doi:10.1017/s003329171700349x · Cited by 149
Rabinak, C. A., Angstadt, M., Lyons, M., Mori, S., Milad, M. R., Liberzon, I., & Luan Phan, K. (2014) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.09.009 · Cited by 146
Wilkinson, S. T., Stefanovics, E., & Rosenheck, R. A. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09475 · Cited by 145 · cited 1×
“Such extensive use of cannabis may have negative effects on PTSD symptoms (e.g., Bonn-Miller et al., 2013; Wilkinson et al., 2015).”
BackgroundKrystal, J. H., Abdallah, C. G., Averill, L. A., Kelmendi, B., Harpaz-Rotem, I., Sanacora, G., Southwick, S. M., & Duman, R. S. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0829-z · Cited by 145
Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H., Amegadzie, S. S., Malone, T. C., Owens, L. T., Ross, S., & Mennenga, S. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00100 · Cited by 128
Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects
Mueller, F., Lenz, C., Dolder, P. C., Harder, S., Schmid, Y., Lang, U. E., Liechti, M. E., & Borgwardt, S. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.54 · Cited by 127
Ketamine accelerates fear extinction via mTORC1 signaling
Girgenti, M. J., Ghosal, S., LoPresto, D., Taylor, J. R., & Duman, R. S. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.026 · Cited by 125
Passie, T., Emrich, H. M., Karst, M., Brandt, S. D., & Halpern, J. H. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1377 · Cited by 117
Self-citationThe early use of MDMA (‘Ecstasy') in Psychotherapy (1977–1985)
Passie, T. (2018) · Drug Science Policy and Law · doi:10.1177/2050324518767442 · Cited by 116
Self-citationKitchiner, N. J., Lewis, C., Roberts, N. P., & Bisson, J. I. (2019) · European Journal of Psychotraumatology · doi:10.1080/20008198.2019.1684226 · Cited by 113 · cited 1×
“Yet, even after multiple modalities of psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity (Steenkamp et al., 2015; Bryant et al., 2016; Kitchiner et al., 2019).”
BackgroundAcute Adverse Reactions to Lsd in Clinical and Experimental use in the United Kingdom
Malleson, N. (1971) · British Journal of Psychiatry · doi:10.1192/bjp.118.543.229 · Cited by 111 · cited 2×
“, flashbacks) when used in medically supervised settings (Cohen, 1960; Malleson, 1971; Johnson et al., 2018).”
BackgroundMethodYoung, M. B., Norrholm, S. D., Khoury, L. M., Jovanovic, T., Rauch, S. A. M., Reiff, C. M., Dunlop, B. W., Rothbaum, B. O., & Howell, L. L. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4684-8 · Cited by 108 · cited 2×
“The effects of MDMA on fear extinction and memory consolidation may be another contributing factor to its therapeutic potential for the treatment of PTSD (Young et al., 2017; Feduccia and Mithoefer, 2018).”
BackgroundSanz, C., Zamberlan, F., Erowid, E., Erowid, F., & Tagliazucchi, E. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00007 · Cited by 107
Stern, C. A. J., da Silva, T. R., Raymundi, A. M., de Souza, C. P., Sato, V., Kato, L., Guimarães, F. S., Andreatini, R., Takahashi, R. N., & Bertoglio, L. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.024 · Cited by 102
Stroud, J. B., Freeman, T. P., Leech, R., Hindocha, C., Lawn, W., Nutt, D. J., Curran, H. V., & Carhart-Harris, R. L. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4754-y · Cited by 101
The Therapeutic Use of Ayahuasca
Labate, B., & Cavnar, C. (2014) · Springer eBooks · doi:10.1007/978-3-642-40426-9 · Cited by 99
Wagner, A. C., Mithoefer, M. C., Mithoefer, A. T., & Monson, C. M. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1589028 · Cited by 92
Inserra, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00330 · Cited by 91
Kuypers, K. P., Dolder, P. C., Ramaekers, J. G., & Liechti, M. E. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117699617 · Cited by 89
Modern History of Medical Cannabis: From Widespread Use to Prohibitionism and Back
Pisanti, S., & Bifulco, M. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.002 · Cited by 85
Cannabinoid interventions for PTSD: Where to next?
Ney, L. J., Matthews, A. J., Bruno, R., & Felmingham, K. L. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.03.017 · Cited by 82
Cannabis and Psychosis: Are We any Closer to Understanding the Relationship?
Hamilton, I., & Monaghan, M. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1044-x · Cited by 79
Bonn‐Miller, M. O., Boden, M. T., Vujanovic, A. A., & Drescher, K. D. (2011) · Psychological Trauma Theory Research Practice and Policy · doi:10.1037/a0026621 · Cited by 75
Steenkamp, M. M., Blessing, E. M., Galatzer-Levy, I. R., Hollahan, L. C., & Anderson, W. T. (2017) · Depression and Anxiety · doi:10.1002/da.22596 · Cited by 75
Aust, S., Gärtner, M., Basso, L., Otte, C., Wingenfeld, K., Chae, W. R., Heuser-Collier, I., Regen, F., Cosma, N. C., van Hall, F., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.02.005 · Cited by 67
Hindocha, C., Cousijn, J., Rall, M., & Bloomfield, M. (2019) · Journal of Dual Diagnosis · doi:10.1080/15504263.2019.1652380 · Cited by 67
Walsh, Z., & Thiessen, M. S. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1474088 · Cited by 66
Pradhan, B., Mitrev, L., Moaddell, R., & Wainer, I. W. (2018) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2018.03.006 · Cited by 63
The Potential Dangers of Using MDMA for Psychotherapy
Parrott, A. C. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.873690 · Cited by 60
Methylenedioxymethamphetamine (MDMA) in Psychiatry: Pros, Cons, and Suggestions
Schenk, S., & Newcombe, D. A. L. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000962 · Cited by 59
What are the psychological effects of using synthetic cannabinoids? A systematic review
Akram, H., Mokrysz, C., & Curran, H. V. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119826592 · Cited by 58
Sessa, B., Sakal, C., O’Brien, S., & Nutt, D. (2019) · BMJ Case Reports · doi:10.1136/bcr-2019-230109 · Cited by 55
Dahlgren, M. K., Laifer, L. M., VanElzakker, M. B., Offringa, R., Hughes, K. C., Staples-Bradley, L. K., Dubois, S. J., Lasko, N. B., Hinojosa, C. A., Orr, S. P., et al. (2018) · Psychological Medicine · doi:10.1017/s003329171700263x · Cited by 55
Zuj, D. V., Palmer, M. A., Hsu, C.-M. K., Nicholson, E. L., Cushing, P. J., Gray, K. E., & Felmingham, K. L. (2016) · Depression and Anxiety · doi:10.1002/da.22463 · Cited by 53
Duclot, F., Perez-Taboada, I., Wright, K. N., & Kabbaj, M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.06.022 · Cited by 52
K. Biezonski, D., & S. Meyer, J. (2011) · Current Neuropharmacology · doi:10.2174/157015911795017146 · Cited by 51
Barrett, F. S., Preller, K. H., Herdener, M., Janata, P., & Vollenweider, F. X. (2018) · Cerebral Cortex · doi:10.1093/cercor/bhx257 · Cited by 51
Heal, D. J., Gosden, J., & Smith, S. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.049 · Cited by 49
Pradhan, B., Wainer, I., Moaddel, R., Torjman, M., Goldberg, M., Sabia, M., Parikh, T., & Pumariega, A. (2017) · Asia Pacific Journal of Clinical Trials: Nervous System Diseases · doi:10.4103/2542-3932.211589 · Cited by 49
Bordieri, M. J., Tull, M. T., McDermott, M. J., & Gratz, K. L. (2014) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2014.08.005 · Cited by 47 · cited 1×
“A possible explanation is that cannabis use can serve as a way to avoid unpleasant experiences (Bonn-Miller et al., 2007; Bordieri et al., 2014).”
BackgroundThe Lingering Impact of Resolved PTSD on Subsequent Functioning
Bryant, R. A., McFarlane, A. C., Silove, D., O’Donnell, M. L., Forbes, D., & Creamer, M. (2016) · Clinical Psychological Science · doi:10.1177/2167702615598756 · Cited by 47
DePierro, J. M., Lepow, L., Feder, A., & Yehuda, R. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.07.009 · Cited by 43
Behavioral Neurobiology of PTSD
(2018) · Current topics in behavioral neurosciences · doi:10.1007/978-3-319-94824-9 · Cited by 43
Ayahuasca as a Candidate Therapy for PTSD
Nielson, J. L., & Megler, J. D. (2013) · Springer eBooks · doi:10.1007/978-3-642-40426-9_3 · Cited by 42
The Lingering Impact of Resolved PTSD on Subsequent Functioning
Bryant, R. A., McFARLANE, A. C., Silove, D. M., O'Donnell, M. L., Forbes, D., & Creamer, M. C. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021016 · Cited by 39
Vizeli, P., & Liechti, M. E. (2018) · PLOS ONE · doi:10.1371/journal.pone.0199384 · Cited by 36
Effective Management Approaches for Psychosis in Patients With Parkinson Disease
Pahwa, R., & Kremens, D. E. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.ad18017su1c · Cited by 36
Das, R., Freeman, T. P., & Kamboj, S. K. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.11.018 · Cited by 32
Chronic cannabis use is associated with impaired fear extinction in humans.
Papini, S., Ruglass, L. M., Lopez-Castro, T., Powers, M. B., Smits, J. A. J., & Hien, D. A. (2017) · Journal of Abnormal Psychology · doi:10.1037/abn0000224 · Cited by 32
Strassman, R. J. (1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.2.249 · Cited by 30
Heifets, B. D., & Malenka, R. C. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1145 · Cited by 29
WHO proposes rescheduling cannabis to allow medical applications
Mayor, S. (2019) · BMJ · doi:10.1136/bmj.l574 · Cited by 24
Veen, C., Jacobs, G., Philippens, I., & Vermetten, E. (2018) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2017_34 · Cited by 23
Self-citationMDMA enhances pleasantness of affective touch
de Wit, H., & Bershad, A. K. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0473-x · Cited by 18
Cannabis and Cannabinoids: From Synapse to Society
Haney, M., & Hill, M. N. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.255 · Cited by 18
Psychedelics and related drugs: therapeutic possibilities, mechanisms and regulation
Curran, H. V., Nutt, D., & de Wit, H. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4822-3 · Cited by 18
Halluzinogene — psychische grenzzustande in forschung und psychotherapie
Schultes, R. E. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90023-0 · Cited by 14
Giese, K.-P., & Radwańska, K. (2015) · Springer eBooks · doi:10.1007/978-3-319-24364-1 · Cited by 13
Halluzinogene : psychische Grenzzustände in Forschung u. Psychotherapie
Leuner, H. (1981) · Huber eBooks · Cited by 10
Ketamine: Its Safety, Tolerability, and Impact on Neurocognition
RYBAKOWSKI, J. K., Permoda‐Osip, A., & Bartkowska‐Śniatkowska, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_5 · Cited by 4
(2017)
Research works printed but not linked: 6
- Bastiaans, 1983, Mental liberation facilitated by the use of hallucinogenic drugs., 143
- Gasser, 1996, Die psycholytische Psychotherapie in der Schweiz von 1988–1993, Schweiz Arch Neurol Psychiatr, 147, 59
- Grof, 1980, LSD psychotherapy
- Ossebaard, 1999, The bastiaans method of drug-assisted psychotherapy, In: MAPS Bulletin, 9, 3
- Passie, 1997, Psycholytic and psychedelic therapy research 1931–1995: a complete international bibliography
- Passie, 2012, Healing with entactogens: therapist and patient perspectives on MDMA-assisted group psychotherapy
Cited by
De Gregorio, D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1659-20.2020 · Cited by 259
The Therapeutic Potential of Psilocybin
Lowe, H., Toyang, N., Steele, B., Valentine, H., Grant, J., Ali, A., Ngwa, W., & Gordon, L. (2021) · Molecules · doi:10.3390/molecules26102948 · Cited by 242
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00748-y · Cited by 224
Self-citationTreatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Burback, L., Brémault-Phillips, S., Nijdam, M. J., McFarlane, A., & Vermetten, E. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230428091433 · Cited by 208
Self-citationSchimmers, N., Breeksema, J. J., Smith-Apeldoorn, S. Y., Veraart, J., van den Brink, W., & Schoevers, R. A. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06027-y · Cited by 162
Self-citation
Metadata
- Authors
- Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E.
- Affiliations
- Leiden University Medical Center (NL)
- University Medical Center Groningen (NL)
- ARQ National Psychotrauma Center, Diemen, The Netherlands
- Goethe University Frankfurt (DE)
- Corresponding author
- Vermetten, Eric
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-03-14
- Volume
- 23
- Issue
- 6
- Pages
- 385-400
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7311646
- OpenAlex
- W3011668650
- Cited by
- 260
- References
- 167
- Citations by year
- 2026: 21 · 2025: 62 · 2024: 54 · 2023: 43 · 2022: 44 · 2021: 24 · 2020: 11
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion, cc-by-nc)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by-nc)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
- Funders
- Universiteit Leiden
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- post-traumatic stress disorder, psychedelics, MDMA, ketamine, psilocybin, LSD, cannabinoids, psychedelic-assisted psychotherapy, adjunctive therapy, psychiatric drug development
- MeSH terms
- Brain, Hallucinogens, Humans, Stress Disorders, Post-Traumatic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.